Comparisons of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors (PCSK9I) versus Ezetimibe on Major Adverse Cardiovascular Events Amongst Patients with Dyslipidaemia: A Population-Based Study

Oscar Hou In Chou, Lifang Li, Cheuk To Skylar Chung, Lei Lu, Quinncy Lee, Hugo Hok Him Pui, Bosco Kwok Hei Leung, Carlin Chang, Tong Liu, Abraham Ka Chung Wai, Gregory Lip, Bernard Man Yung Cheung, Gary Tse, Jiandong Zhou
doi: https://doi.org/10.1101/2023.09.23.23296003
Back to top
Posted September 25, 2023.
Download PDF

Supplementary Material

Data/Code
Email
Comparisons of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors (PCSK9I) versus Ezetimibe on Major Adverse Cardiovascular Events Amongst Patients with Dyslipidaemia: A Population-Based Study
Oscar Hou In Chou, Lifang Li, Cheuk To Skylar Chung, Lei Lu, Quinncy Lee, Hugo Hok Him Pui, Bosco Kwok Hei Leung, Carlin Chang, Tong Liu, Abraham Ka Chung Wai, Gregory Lip, Bernard Man Yung Cheung, Gary Tse, Jiandong Zhou
medRxiv 2023.09.23.23296003; doi: https://doi.org/10.1101/2023.09.23.23296003
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area